News of Note—BioLineRx financing; Ablynx fast track; Ophthotech pivot; Dynavax briefing documents

Newspapers

> BioLineRx secured a $9.6 million investment from its largest shareholder. The Novartis-partnered biotech raised the money from BVF Partners to fund clinical development. Release

> The FDA awarded fast-track status to Ablynx’s caplacizumab in acquired thrombotic thrombocytopenic purpura. Ablynx is planning to file for FDA approval of the anti-von Willebrand factor single-domain antibody next year. The fast-track nod means caplacizumab is eligible for priority review by the regulator. Statement

> Ophthotech pivoted into rare diseases. The biotech plans to test C5 complement inhibitor Zimura in Stargardt disease. Ophthotech’s interest in testing the drug in rare diseases follows setbacks to its ambition to treat age-related retinal conditions. Release

Whitepaper

Overcoming Risk in Oncology Drug Development

Oncology drug development is full of potential obstacles and risks, and you must carefully plan each step. Download this whitepaper for tips on finding the fast track. Premier Research. Built for Biotech.

> The FDA has published the briefing documents for an advisory committee meeting about Dynavax’s hepatitis B vaccine. Documents (PDF)

Suggested Articles

The company, which was co-founded by Jim Mellon, has reeled in $165 million in 18 months to establish itself at the forefront of the longevity field.

The FDA broadened its approval of Medtronic’s transcatheter aortic valve replacement to include patients at a low risk of surgical complications.

The FDA approved the first spinal tether to correct the most common form of scoliosis—a ropelike implant that pulls the vertebrae into shape.